Khiron Life Sciences Corp. (TSXV:KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a cannabis company with core operations in Latin America, today announced the appointment of Wendy Kaufman as CFO, effective July 2, 2019. Ms. Kaufman, a Chartered Professional Accountant, brings over 20 years of international financial experience, having served most recently as CFO at Pasinex Resources Limited.  Ms. Kaufman has significant experience with Latin American operations, gained during her tenure as CFO at Primero Mining Corporation, and previously in her role as Vice President, Finance and Treasury at Inmet Mining Corporation, among other executive management positions.

Alvaro Torres, CEO of Khiron, stated, “On behalf of our management team and Board of Directors, I welcome Wendy to Khiron.  We are confident that Wendy’s financial leadership and experience will be of great value to Khiron and our stakeholders as we continue to grow our operations and brands in Latin America and internationally.”


Ms. Kaufman will be replacing Mr. Darren Collins who has concurrently resigned his position as CFO to pursue other interests.  Mr. Collins has agreed to remain with the Company for an appropriate period in a transitional role.  Mr. Torres stated, “On behalf of the Board of Directors and the entire Khiron team, I would like to thank Darren for his invaluable contributions and leadership as the founding CFO of the company.  Darren has helped to build Khiron into the company it is today.  We wish him the very best in his future endeavors.”

About Khiron Life Sciences Corp.

Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian based cannabis company to trade on any exchange globally.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Further information on Khiron Life Sciences can be found at www.khiron.ca.

To be added to the distribution list, please email khiron@kcsa.com with “Khiron” in the subject line.

Cautionary Notes

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN) for an Investor Presentation. 

Source: www.prnewswire.com

Cannabis research firm New Frontier Data has released a new report in which it projects that the value of the total cannabis industry will reach US$51 billion by the year 2025.

Also this week, a few cannabis companies announced new international ventures. This side of the space is full of potential, but is relatively new compared to markets like the US and Canada.

Keep reading... Show less

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“the Company”) today announced that it has officially launched its new cold storage services for 3rd party manufacturers with the onboarding of its first client, Kase Manufacturing (‘Kase’).

Kase will rent portions of TransCanna‘s 4,400 square foot, state-of-the-art cold storage cannabis freezer for specialized storage of Kase’s fresh-frozen cannabis biomass. The sub-40 degree Fahrenheit cannabis freezer, roughly the size of a five bedroom house, is the largest of its kind in Northern California.

Keep reading... Show less

Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company”), an established Canadian cannabis and vape retailer, is pleased to announce that further to its press release dated August 26, 2021, all of its issued and outstanding common shares (the “Common Shares”) will begin trading on a post-consolidation basis on September 17, 2021 at the commencement of trading on the TSX Venture Exchange (“TSXV”).

On August 26, 2021, the Company announced that the Common Shares would be consolidated on the basis of one (1) post-consolidation Common Share for each five (5) pre-consolidation Common Shares (the “Share Consolidation“).

Keep reading... Show less

 TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced that it has received pre-qualification approval for cultivation, processing and retail licenses from the state of Michigan’s Marijuana Regulatory Agency pursuant to the Medical Marihuana Facilities Licensing Act. The pre-qualification approval represents TerrAscend’s successful completion of the most comprehensive portion of the State’s licensing and regulatory approval process. The pre-qualification approval is a key closing condition for TerrAscend’s previously announced acquisition of Gage Growth Corp.(“Gage”) (the “Transaction”). The Transaction will close as soon as possible after receipt of the applicable shareholder, court and other regulatory approvals and satisfaction or waiver of all other conditions in the definitive arrangement agreement (the “Arrangement Agreement”).

Keep reading... Show less

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness Company offering premium probiotic supplements and products containing CBD, is pleased to announce it has increased the size of its previously announced non-brokered private placement from USD $2,000,000 to over USD $2,500,000 (the “Private Placement”). This increase is designed to accommodate additional demand that the Company has received in the financing.

Keep reading... Show less